Matthew David Galsky

Title: The Innovative Contributions of Matthew David Galsky

Introduction

Matthew David Galsky is a prominent inventor based in New Rochelle, NY (US). He has made significant strides in the field of anti-cancer therapeutics, holding 2 patents that focus on innovative methods for treating cancer. His work is crucial in the ongoing battle against various forms of cancer, particularly non-small cell lung cancer.

Latest Patents

Galsky's latest patents include a method and compositions for treating cancer. This invention relates to anti-cancer therapeutics that utilize a combination of an anti-EGFR agent and agents that enhance the activity of tumor suppressor genes such as KLF6 and FOXO1. In a preferred aspect, the anti-EGFR agent erlotinib is combined with a tricyclic agent compound to treat patients with primary or acquired drug resistance to erlotinib. The tricyclic agent is administered in a manner that avoids significant central nervous system effects. Additionally, the invention encompasses compositions and kits for treating cancers, methods for screening compounds that enhance the activity of the anti-EGFR agent, and methods for determining patient responses to anti-EGFR therapy.

Career Highlights

Matthew David Galsky is affiliated with the Icahn School of Medicine at Mount Sinai, where he contributes to groundbreaking research in cancer treatment. His work is recognized for its potential to improve therapeutic outcomes for patients suffering from challenging cancer types.

Collaborations

Galsky collaborates with esteemed colleagues such as Goutham Narla and Michael H Ohlmeyer, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Matthew David Galsky's innovative contributions to cancer treatment exemplify the vital role of inventors in advancing medical science. His patents and research efforts are paving the way for more effective therapies, ultimately benefiting patients in need.